Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 4/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | NT5C2 | P49902 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19555386 | 0.84 | GDA (0.42) | GDAXDHGAABRD4NPC1 | |
| SCHEMBL19409219 | 0.82 | GDA (0.41) | GDAXDHTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL13348706 | 0.73 | — | — | |
| SCHEMBL71570 | 0.72 | — | — | |
| SCHEMBL28758025 | 0.72 | GDA (0.47) | GDAGABRR1GAATDP1L3MBTL1 | |
| SCHEMBL6334335 | 0.72 | GABRR1 (0.36) | XDHGABRR1GAABRD4TDP1 | |
| SCHEMBL22118770 | 0.72 | BRD4 (0.40) | GAABRD4HSD17B10NPC1RAB9A | |
| SCHEMBL29654971 | 0.72 | BRD4 (0.40) | GAABRD4HSD17B10NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9595105 | 0.71 | GDA (0.46) | GDAGABRR1GAATDP1L3MBTL1 | |
| SCHEMBL19409247 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | GDA 50/4885XDH 1556/4885GABRR1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.